Clinical trial
Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1
NCT00948220 is registered in ClinicalTrials.gov with University of Ulm as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Non-randomized Prospective Study on the Effect of Antiviral Therapy With Peginterferon Alfa-2a and Ribavirin on Bone Mineral Density and Metabolism in Patients With Chronic Viral Hepatitis C Genotype 1
- Lead sponsor
- University of Ulm
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- July 31, 2003
- Completion date
- March 31, 2008
- Enrollment
- 26 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.